GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vicapsys Life Sciences VICP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.50

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2017FY2025

Net income

−$689,887

FY2017FY2025

Free cash flow

−$21,466

FY2017FY2025

Shareholders' equity

−$3.6m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue———————$742,586—
Gross profit———−$31,288−$31,329—−$31,299−$126,843−$178,978
Research and development$567$14,090$15,267$13,097$17,698$102,180$98,983$98,752$233,023
Operating income−$651,803−$813,836−$1.0m−$984,790−$336,871−$765,844−$1.0m−$1.3m−$3.2m
Net income−$689,887−$989,798−$1.2m−$984,790−$236,871−$765,844−$1.4m−$2.2m−$3.2m
Diluted earnings per share-0.02-0.03-0.04-0.03-0.01-0.04-0.08-0.23-0.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$2,637$11,600$39,656$72,021$594,313$404,118$698,439$796,331$1.1m
Cash and short-term investments$2,637$11,600—$14,097$217,295—$264,166$86,330$547,598
Total liabilities$3.6m$2.9m$2.0m$1.0m$715,964$853,224$396,482$1.1m$1.0m
Debt$624,346$578,950———————
Shareholders' equity−$3.6m−$2.9m−$1.9m−$950,791−$121,651−$449,106$301,957−$253,672$47,179
Shares outstanding35m32m32m31m18m17m17m10m35m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$21,463−$121,656−$417,524−$238,197−$443,974−$262,897−$970,264−$2.1m−$3.2m
Capital spending−$3−$4—−$3−$4——−$38,019−$4,127
Free cash flow−$21,466−$121,660−$417,524−$238,200−$443,978−$262,897−$970,264−$2.1m−$3.2m

Latest quarters

By quarter end

Mar 2026Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
Operating income−$96,319−$173,177−$228,878−$527,207−$181,841−$204,255−$527,207−$175,423
Net income−$104,569−$181,427−$237,128−$594,803−$190,091−$327,072−$594,803−$240,340
Diluted earnings per share-0.00-0.01-0.01-0.02-0.01-0.01-0.02-0.01
Total assets$132,542$5,876$11,600$39,656——$39,656$208,486
Cash and short-term investments$132,542$5,876$11,600$9,422———$53,532
Debt$624,346$578,950$578,950$353,868———$307,252
Shareholders' equity−$3.5m−$3.1m−$2.9m−$1.9m−$2.4m−$2.3m−$1.9m−$1.3m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-12.9%-3.2%-12.1%
Net income-11.2%-2.1%-11.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-35.7-6.7-0.1-0.0-0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return239%3898%371%440%146%0%-13%-24%162%29643%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 2 Nov 2017
  • 35-to-1 reverse split · 22 Feb 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.